Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sophie Kervyn
Observed name:
Kervyn, Sophie
Institution:
UCB Pharma (Belgium)
Observed institutions:
National Centre for the Replacement Refinement and Reduction of Animals in Research,
UCB Pharma (Belgium)
OpenAlex ID:
A5002642580
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV 2A ligand for epilepsy treatment
2016
·
Henrik Klitgaard
, Alain Matagne
, et al.
·
Epilepsia
·
189
PDF
Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A ( SV 2A) ligand with preclinical evidence of high brain permeability and fast onset of action
2015
·
Jean‐Marie Nicolas
, Jonas Hannestad
, et al.
·
Epilepsia
·
181
PDF
A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development
2007
·
Sally Robinson
, Jean-Luc Delongeas
, et al.
·
Regulatory Toxicology and Pharmacology
·
114
A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studies
2013
·
Kathryn Chapman
, Fiona Sewell
, et al.
·
Regulatory Toxicology and Pharmacology
·
78
A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers
2019
·
Sjoerd J. Finnema
, Samantha Rossano
, et al.
·
Epilepsia
·
64
PDF
Science‐Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels
2022
·
Christopher J. Bowman
, Nathalie Becourt‐Lhote
, et al.
·
Clinical Pharmacology & Therapeutics
·
22
PDF
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A
2022
·
Mika Naganawa
, Jean-Dominique Gallezot
, et al.
·
EJNMMI Research
·
12
PDF
Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative
2020
·
Jamie K. DaSilva
, Laura Breidenbach
, et al.
·
Journal of Pharmacological and Toxicological Methods
·
11
In Vitro Pharmacokinetic Profile of Brivaracetam (BRV) Reveals Low Risk of Drug-Drug Interaction (DDI) and Unrestricted Brain Permeability (P4.276)
2015
·
Hugues Chanteux
, Sophie Kervyn
, et al.
·
Neurology
·
10
Brivaracetam enters the brain faster than levetiracetam: a PET study in healthy volunteers (P6.233)
2017
·
Sjoerd J. Finnema
, Joel Mercier
, et al.
·
Neurology
·
9
N-Alkylprotoporphyrin Formation and Hepatic Porphyria in Dogs After Administration of a New Antiepileptic Drug Candidate: Mechanism and Species Specificity
2014
·
Jean-Marie Nicolas
, Hugues Chanteux
, et al.
·
Toxicological Sciences
·
9
Challenging the regulatory requirement for conventional acute toxicity studies in pharmaceutical drug development
2007
·
Sally Robinson
, Deborah Ockert
, et al.
·
Toxicology
·
7
Reprint of: Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative
2020
·
Jamie K. DaSilva
, Laura Breidenbach
, et al.
·
Journal of Pharmacological and Toxicological Methods
·
2
Brivaracetam (BRV) Achieves Brain SV2A Occupancy Faster than Levetiracetam (LEV) (S22.003)
2015
·
Joel Mercier
, Daniel Holden
, et al.
·
Neurology
·
2
A review of the drug–drug interactions of the new antiepileptic drug brivaracetam (P4.109)
2017
·
Brian Moseley
, Sophie Kervyn
, et al.
·
Neurology
·
1
Challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development
2007
·
Sally Robinson
, Vicente Nogués
, et al.
·
Toxicology Letters
·
1
Show more works
View as search
Works count:
18
Citation count:
712
H-index:
9
I10-index:
9
Year
Topic
Type